| Questcor Pharma beats by $0.17, beats on revs ( QCOR) 25.93 -0.33 : Reports Q3 (Sep) GAAP earnings of $0.91 per share, $0.17 better than the Capital IQ Consensus Estimate of $0.74; revenues rose 134.6% year/year to $140.3 mln vs the $127.75 mln consensus. Questcor shipped 5,590 vials of Acthar during the third quarter 2012, up 92 percent compared to 2,910 vials in the year ago quarter. "Based on information available as of this release, patients with serious, difficult-to-treat medical conditions addressed by Acthar on-label indications have continued to have access to Acthar through commercial insurance, Medicare, Medicaid and other government programs, as well as through our free drug program for uninsured patients. Acthar is most commonly prescribed by physicians as an appropriate treatment alternative for patients in whom first-line therapies have not provided the intended treatment outcome and an additional FDA-approved treatment alternative is needed. For such patients, insurance coverage for Acthar continued to remain favorable." The Company used $58.1 million in cash to repurchase 1,484,300 shares of its common stock in open market transactions, at an average price of $39.15 per share, during the third quarter of 2012. |
